~~<i id='75F66323CD'><strike id='75F66323CD'><tt id='75F66323CD'><pre id='75F66323CD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：comprehensive 2025-09-27 22:18:21 - browse：546

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an experimental pill to treat psoriasis, for $2.4 billion in cash.

The deal price of $48 per share represents a 42% premium to DICE’s closing price Friday.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer, said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Black vets could get higher VA benefits if race not used in lung test

entertainment

knowledge

focus

explore

focus

AdobeMysonThomashascarriedaroundaneedlesinceheenteredkindergartenattheageof5.Thatwasabigresponsibili

WSS

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Primary care doctor shortage won't be solved by free med school tuition

Empower primary care with adequate payments and technology

U.K. sequencing study surfaces new findings about tumor DNA

Can gargling with Listerine treat gonorrhea of the mouth?

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

knowledge

fashion

entertainment

Medical records are filled with copy

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Wildfire smoke exposes gaps in outdoor worker protections

Ahead of JPM, here's who's profiting most in health care

The cancer drug shortage isn’t new — and neither are the solutions

Novel spinal cord stimulator treats paralysis without surgery

United colonoscopy coverage change 'may cost lives,' doctors say

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

DIEP, the 'gold standard' of breast reconstruction, is under threat

White House finalizes ITC's import ban of latest Apple Watches

knowledge

Crowdfunding for medical bills sidesteps core problem, author says

The biotech scorecard for Q1: 17 stock

Warren pushes Witty on UnitedHealth's control over physicians

3 trends to watch in health tech's hiring outlook for 2024

Has Bernie Sanders reached the limit of his pharma bullying effort?

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

explore

focus

focus